Filing Flows › Viridian Therapeutics (VRDN) › Q3 2026 › vs Q3 2025
Viridian Therapeutics (VRDN) Q3 2026 vs Q3 2025 (year over year)
Viridian Therapeutics's revenue fell $44.8M (-64%) from $70.6M in Q3 2025 to $25.8M in Q3 2026. The biggest changes: License revenue −$69.9M (-100%); Product revenue, net +$24.7M (—); Collaboration revenue +$386K (+68%).
Viridian Therapeutics, Q3 2026: revenue $25.8M (-64% year over year), operating margin -401.8%, net loss $101M, operating cash flow −$92.8M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Product revenue, net | $24.7M | $0 | $24.7M | — |
| Collaboration revenue | $956K | $570K | $386K | +68% |
| License revenue | $125K | $70.0M | −$69.9M | -100% |
| Revenue | $25.8M | $70.6M | −$44.8M | -64% |
| Other income, net | $2.3M | $5.4M | −$3.1M | -58% |
| Net loss | $101M | $34.6M | $66.6M | +193% |
| Costs & expenses | $129M | $111M | $18.6M | +17% |
| Operating costs | $129M | $111M | $18.6M | +17% |
| Research & development | $70.1M | $86.3M | −$16.2M | -19% |
| SG&A | $57.6M | $24.3M | $33.3M | +137% |
| Operating cash sources | $110M | $96.0M | $14.4M | +15% |
| Depreciation & amortization | $343K | $110K | $233K | +212% |
| Share-based compensation | $17.2M | $11.2M | $6.0M | +53% |
| Cash used in operations | $92.8M | $84.6M | $8.2M | +10% |
| Net loss absorbed | $101M | $34.6M | $66.6M | +193% |
| Working capital & other | $9.1M | $61.4M | −$52.2M | -85% |
Questions
How much did Viridian Therapeutics's revenue grow year over year in Q3 2026?
Viridian Therapeutics's revenue fell $44.8M (-64%) from $70.6M in Q3 2025 to $25.8M in Q3 2026.
What drove Viridian Therapeutics's revenue change in Q3 2026?
License revenue −$69.9M (-100%); Product revenue, net +$24.7M (—); Collaboration revenue +$386K (+68%).